MedTrace Logo

A Study of Multiple Ascending Doses MY008211A in Healthy Adults

NCT05828472 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-09-08

No results posted yet for this study

Summary

This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation, and multiple-dose study to evaluate safety, tolerability, PK and PD of MY008211A Tablets in healthy subjects.

Conditions

Interventions

DRUG

MY008211A tablets

MY008211A tablets, low/moderate/high dose orally, for 7 days

DRUG

MY008211A tablets matched placebo

MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days

Sponsors & Collaborators

  • Wuhan Createrna Science and Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Wei feng, Ph.D · Wuhan Createrna Science and Technology Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05828472 on ClinicalTrials.gov